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Context: Current American Thyroid Association (ATA) Management Guidelines for the 
treatment of differentiated thyroid cancer (DTC) stratify patients to decide on additional 
radioiodine (RAI) therapy after surgery, and to predict recurring/persisting disease. However, 
studies evaluating the detection of distant metastases and how these guidelines perform in 
patients with distant metastases are scarce.
Objective: To evaluate the 2015 ATA Guidelines in DTC patients with respect to 1) the detection 
of distant metastases, and 2) the accuracy of its Risk Stratification System in patients with 
distant metastases.
Patients and Main Outcome Measures: We retrospectively included 83 DTC patients who were 
diagnosed with distant metastases around the time of initial therapy, and a control population of 
472 patients (312 low-risk, 160 intermediate-risk) who did not have a routine indication for RAI 
therapy. We used the control group to assess the percentage of distant metastases that would have 
been missed if no RAI therapy was given.
Results: Two hundred forty-six patients had no routine indication for RAI therapy of which 4 
(1.6%) had distant metastases. Furthermore, among the 83 patients with distant metastases, 
14 patients (17%) had excellent response, while 55 (67%) had structural disease after a median 
follow-up of 62 months. None of the 14 patients that achieved an excellent response had a 
recurrence.
Conclusions: In patients without a routine indication for RAI therapy according to the 2015 ATA 
Guidelines, distant metastases would initially have been missed in 1.6% of the patients. Furthermore, 
in patients with distant metastases upon diagnosis, the 2015 ATA Guidelines are an excellent 
predictor of both persistent disease and recurrence. (J Clin Endocrinol Metab 105: 1–9, 2020)
Key Words:  differentiated thyroid cancer, survival, prognosis, recurrence, American thyroid 
association guidelines, distant metastases
The worldwide incidence of differentiated thyroid cancer (DTC) has been steadily increasing over the last 2 dec-
ades (1, 2). As mortality has remained stable to slightly 
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increasing, a less aggressive therapeutic approach seems 
appropriate (1–4). To optimize the need for de-escalation 
of therapy and follow-up strategies, different systems that 
predict the risk of recurrence and survival in patients with 
DTC have been proposed and evaluated (3, 5–9).
The current 2015 American Thyroid Association 
(ATA) Management Guidelines use their own Risk 
Stratification System to determine the need for 
radioiodine (RAI) therapy after surgery (3). However, 
this approach has been challenged by several experts 
in the field (10–12). Because one of the aims of RAI 
therapy is to treat any remaining unknown cancer tissue, 
omitting RAI therapy might leave undetected metastases 
untreated (11). Using the criteria defined in the 2015 
ATA Guidelines, one study claimed that a substantial 
proportion of patients with distant metastatic disease 
would not have been treated with RAI and thereby 
would have been missed (13). However, this study also 
included patients in whom metastatic disease was diag-
nosed during follow-up. Another study showed, in low- 
and intermediate-risk patients defined by the 2009 ATA 
Guidelines, that 1% of the distant metastases would 
have been missed with omission of RAI therapy (14).
Several studies show that patients with distantly me-
tastasized DTC have a relative poor prognosis (15–21). 
Risk factors such as age, RAI avidity, tumor size, and fol-
licular type influence this prognosis (15–23). However, 
to our knowledge, no studies yet evaluated the 2015 
ATA Risk Stratification System in DTC patients with 
distant metastases with respect to its ability to predict 
prognosis, recurrence, and survival.
We initiated the current study because 1) there are very 
few studies evaluating risk factors in distant metastatic 
disease identified before or during initial therapy, 2) only 
2 studies, both having limitations, have so far evaluated 
the consequences of omitting RAI therapy according to 
the new ATA Guidelines on the proportion of possible un-
detected distant metastases (13, 14), and 3) no studies have 
yet evaluated the 2015 ATA Risk Stratification System in 
DTC patients with distant metastases. The aim of our 
study was to evaluate the 2015 ATA Guidelines in DTC 
patients with respect to 1) the proportion of possible dis-
tant metastases, and 2) the performance of the ATA Risk 
Stratification System in patients with distant metastases.
Materials and Methods
Study population and clinical outcomes
We retrospectively identified all patients, aged 16 years or 
older, who were diagnosed and/or treated for either papil-
lary (PTC) or follicular (FTC) thyroid carcinoma (including 
Hürthle cell carcinoma) at the Erasmus Medical Center, 
Rotterdam, The Netherlands, from January 2002 to December 
2016. For the current study, we included all patients who 
underwent thyroid surgery followed by RAI therapy, which is 
in line with the 2015 Dutch Thyroid Cancer Guidelines (24). 
Patients included were 1) diagnosed with distant metastases 
either before initial RAI therapy based on pathology or im-
aging such as computed tomography (CT) (pre-RAI group) 
or directly afterwards using the posttherapy whole-body scan 
(post-RAI group); or 2) had DTC classified as either ATA low- 
or intermediate-risk (according to the 2015 ATA Guidelines). 
We used data from the patients with distant metastases (pre- 
and post-RAI group) to assess the performance of the Risk 
Stratification System. The ATA low- and intermediate-risk 
groups served as control groups for the calculation of the 
proportion of undetected distant metastases when omitting 
RAI therapy. In a previous publication (25), we evaluated 
the Risk Stratification System of the 2015 ATA Guidelines 
in 236 high-risk DTC patients, also including patients with 
metastatic disease treated in our institute (n = 78). In the cur-
rent study, which only focuses on the metastatic group and 
investigates this in much greater detail, we included 74 of the 
patients from this previous publication plus some additional 
patients with metastatice disease.
From patient records, we obtained demographic, disease, 
treatment, response to therapy, recurrence, and mortality 
characteristics. Demographic variables included age at diag-
nosis, sex, and year of diagnosis. Disease characteristics in-
cluded disease type, TNM-stage (8th edition), tumor size, 
presence/absence of multifocal disease, presence/absence of 
vascular invasion, presence/absence of lymph node metas-
tases, and minor/gross extrathyroidal extension (ETE). Data 
regarding treatment consisted of extent of surgery, use of RAI, 
and use of other treatment modalities (eg, external beam radi-
ation therapy [EBRT]).
Indication for RAI therapy was retrospectively reassessed 
using the 2015 ATA Guidelines (3) in 1) the post-RAI group, 
ignoring knowledge about the found distant metastases, and 
2) the control groups. RAI therapy is routinely recommended 
in ATA high-risk patients, should be considered in ATA 
intermediate-risk patients, is not routinely recommended in 
ATA low-risk patients with tumors larger than 1 and smaller 
than 4 cm, and is not given in ATA low-risk patients with tu-
mors of 1 cm or smaller. The current and past Dutch Guidelines 
recommend to always treat patients with RAI therapy after a 
total thyroidectomy; a total thyroidectomy is always indicated 
in tumors ≥ 1 cm.
Response to therapy was defined according to the 4 
categories described in the 2015 ATA Guidelines and was con-
tinually assessed during follow-up (ie, dynamic risk stratifica-
tion [DRS]) (3). Patients were considered to have an excellent 
response to therapy (ie, no evidence of disease [NED]), if they 
had a suppressed thyroglobulin (Tg) < 0.2 ng/mL or thyro-
tropin (also known as thyroid-stimulating hormone; TSH)-
stimulated Tg < 1  ng/mL, no detectable antibodies, and no 
evidence of structural disease on imaging. Patients were con-
sidered to have biochemical incomplete response if they had a 
suppressed Tg ≥ 1 ng/mL or stimulated Tg ≥ 10 ng/mL or rising 
anti-Tg antibody levels, but no evidence of structural disease 
on imaging. Patients were considered to have structural in-
complete response if they had structural evidence of disease 
on imaging. And finally, patients were considered to have in-
determinate response if they had a suppressed Tg < 1 ng/mL 
or a stimulated Tg  <  10  ng/mL, declining or stable anti-Tg 
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antibody levels. Persistent disease was defined as either 
structural or biochemical incomplete response. Response to 
therapy was recorded for the first time 6 to 18 months after 
the first therapy (ie, initial DRS); thereafter during and at end 
of follow-up. A recurrence was defined as new biochemical or 
structural disease after longer than 12 months of NED.
RAI refractory disease was defined according to the 2015 
ATA Guidelines (3), ie, 1)  the malignant/metastatic tissue 
never concentrated RAI, 2) the tumor tissue loses the ability to 
concentrate RAI after previous evidence of RAI-avid disease, 
3)  RAI is concentrated in some lesions but not in others, 
4) metastatic disease progresses despite significant concentra-
tion of RAI. Additionally, we also considered patients with a 
stimulated Tg ≥ 30 ng/mL without significant concentration of 
RAI as having RAI-refractory disease.
Time to last follow-up, survival status, and date and cause 
of death were recorded. Survival was defined as the time of 
initial diagnosis to either last date of follow-up, death, or end 
of study (December 2017), whichever occurred first. Cause 
of death was obtained from hospital or general practitioner 
records. Patients with extensive or rapidly progressive thyroid 
cancer and no clear other cause of death were classified as death 
due to thyroid cancer. The study protocol was approved by the 
institutional review board of the Erasmus Medical Center.
Statistical analysis
For continuous variables, means and standard deviations 
(SD), or medians with interquartile ranges (IQR) were calcu-
lated. For categorical variables, absolute numbers with percent-
ages were recorded. To assess the influence of the 2015 ATA 
Guidelines on the occurrence of possible undetected distant 
metastases, we compared the post-RAI and control group. 
Thereafter, differences in characteristics between the pre- and 
post-RAI groups were assessed using the Student’s t-test or χ 2-
test. Overall survival (OS) and disease-specific survival (DSS) 
were analyzed using the Kaplan-Meier method for the patients 
with distant metastases. The same analyses were also performed 
for the pre- and post-RAI groups, and for the control popu-
lation separately. In the pre- and post-RAI groups, univariate 
and multivariate logistic regression or Cox proportional haz-
ards models were used to examine the effect of different (poten-
tial) risk factors on either response to therapy (at first DRS and 
at final follow-up), developing NED, recurrence, or survival. 
Data on these (potential) risk factors were missing in 4% of 
the values; due to this low percentage, a patient was left out 
from the corresponding analysis if a value was missing. P values 
below 0.05 were considered significant. All analyses were per-
formed using SPSS Statistics for Windows (version 24.0).
Results
Population characteristics
During the study period, a total of 85 patients with 
distant metastases, 312 with ATA low-risk, and 160 
with ATA intermediate-risk disease were eligible for 
the study. Two of the patients with distant metastases 
were excluded because of insufficient data on follow-up, 
leaving 83 patients available for analyses.
Table 1 lists the characteristics of the study popula-
tion with distant metastases. Mean age was 56.3 years, 
and 57 (69%) were women. Distant metastatic disease 
was identified before RAI therapy (pre-RAI group) in 
33 (40%) patients. In these 33 patients, these metastases 
were discovered either because of symptoms (30%; 
eg, pain), during preoperative staging because of large 
tumor burden in the neck (27%), or incidentally dis-
covered on a CT or fluorodeoxyglucose-positron emis-
sion tomography (FDG-PET) made for another reason 
(21%). On the other hand, in the remaining 50 (60%) 
patients, the distant metastases were detected directly 
after RAI therapy by the posttherapy whole-body scan 
(post-RAI group). PTC was present in 53 (64%) patients 
(including 10 (19%) with follicular variant of PTC), and 
the remaining 30 patients (36%) had FTC, including 7 
patients (8%) with Hürthle Cell carcinoma. Median 
follow-up time was 62  months; during follow-up, 30 
patients (36%) died, of which 26 were due to thyroid 
cancer. Total thyroidectomy was performed in all pa-
tients except 1 who received a hemithyroidectomy be-
cause of presence of one-sided recurrent nerve paralysis. 
All patients received RAI therapy (19 [23%] once, 21 
[25%] twice, and 43 [52%] received more than 2 ther-
apies). Neck dissection was performed in 40 (48%) pa-
tients (central in 6 [7%], lateral in 5 [6%], and both in 29 
[35%]). Patients in the pre-RAI group were significantly 
older (62.5 years vs 52.3 years; P < 0.001), had signifi-
cantly more often FTC (58% vs 22%; P = 0.001), and 
received more often EBRT (46% vs 18%; P  = 0.008) 
than those in the post-RAI group. There were no differ-
ences between the pre- and post-RAI groups regarding 
elevated Tg, presence of lymph node metastases or gross 
ETE. The only difference was that patients in the post-
RAI group more often had multifocal disease (26).
Influence of the 2015 ATA guidelines
We retrospectively re-evaluated the indication for 
RAI therapy in the 50 post-RAI patients. For 1 patient, 
insufficient information was available to assess the 
initial risk category. Of the remaining 49 patients, 39 
(80%) were ATA high-risk, 6 (12%) were intermediate-
risk, and 4 (8%) were low-risk. These 4 patients with 
low-risk disease would not have been treated with 
RAI therapy according to the 2015 ATA Guidelines, 
while for the 6 intermediate-risk patients, RAI therapy 
should have been considered (see Table 2). The 10-year 
DSS for these 49 patients was 100% in the low-, 80% 
in the intermediate-, and 68% in the high-risk group 
(P = 0.607).
As previously mentioned, the control population 
of ATA low- and intermediate-risk patients consisted 
of 472 patients who all received total thyroidectomy 
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followed by RAI therapy according to 2015 Dutch 
Thyroid Cancer Guidelines (26). According to the 2015 
ATA Guidelines, 54 (11%) should not, and 188 (40%) 
would not routinely have been treated with RAI, while 
in 230 (49%) treatment with RAI therapy should have 
been considered (26). The 10-year DSS in the control 
group was 99.8%. Combining the groups in which RAI 
therapy should not or would not routinely have been 
given according to the 2015 ATA Guidelines resulted 
in 246 patients (ie, 4 + 54 + 188) of whom 4 (1.6%) 
had distant metastatic disease that would have been ini-
tially missed if no RAI therapy would have been given. 
The group in which RAI therapy should be considered 
consisted of 236 patients (ie, 6 + 70 + 160) in which 6 
(2.5%) distant metastases would have been missed if it 
were decided not to treat them with RAI. No in-depth 
investigation of possible risk factors to identify distant 
metastatic disease before initial therapy was possible in 
these patients; characteristics of the 4 low-risk patients 
are presented in Table 3.
Combining the pre- and post-RAI groups, while 
purposefully not accounting for the knowledge of the 
presence of distant metastases that was known upfront, 
Table 2. Indication for RAI Therapy (2015 ATA 
Guidelines) in the Post-RAI Group in Whom Distant 
Metastases Would Have Been Missed if RAI Therapy 
was Omitted
RAI  
Indication
ATA Low-Risk 
(n = 4)a
ATA  
Intermediate- 
Risk (n = 6)a
ATA  
High-Risk 
(n = 39)a
No - - -
Not routine 4 (8%) - -
Consider - 6 (12%) -
Yes - - 39 (80%)
aValues are numbers (percentages). Abbreviations: ATA, American Thy-
roid Association.
Table 1. Characteristics of the Study Population
Total Population  
(n = 83)a
Pre-RAI Group  
(n = 33)a
Post-RAI Group  
(n = 50)a P Valueb
Age at diagnosis (years) 56.3 ± 20.0 62.5 ± 17.9 52.3 ± 20.4 <0.001
Women 57 (69%) 20 (61%) 37 (74%) 0.198
Histopathological subtype     
 Papillary 53 (64%) 14 (42%) 39 (78%) 0.001
 Follicular 30 (36%) 19 (58%) 11 (22%)
 Hürthle Cell 7 (8%) 5 (15%) 2 (4%) 0.074
AJCC/TNM Staging system (8th)     
 I - - - 0.051
 II 36 (43%) 10 (30%) 26 (52%)
 III - - -
 IV 47 (57%) 23 (70%) 24 (48%)
Tumor Size (cm) 3.5 (2.0–5.2) 4.1 (1.7–6.6) 3.5 (2.1–5.0) 0.668
Metastatic disease 83 (100%) 34 (100%) 50 (100%) -
 Pulmonary 64 (77%) 22 (67%) 42 (84%) 0.071
 Bone 24 (29%) 12 (36%) 12 (24%) 0.145
 Pulmonary and Bone 12 (15%) 4 (12%) 8 (16%) 0.902
Surgery (TT or HT) 83 (100%) 33 (100%) 50 (100%) -
 HT 1 (1%) 1 (3%) - 0.216
 TT 82 (99%) 32 (97%) 50 (100%)
Neck dissection 40 (48%) 14 (42%) 24 (48%) 0.226
 Central 6 (7%) 2 (6%) 4 (8%) 0.131
 Lateral 5 (6%) 4 (12%) 1 (2%)
 Both 29 (35%) 8 (24%) 21 (42%)
RAI treatment 83 (100%) 33 (100%) 50 (100%) -
 Once 19 (23%) 11 (33%) 8 (16%) 0.115
 Twice 21 (25%) 9 (27%) 12 (24%)
 ≥ 3 43 (52%) 13 (39%) 30 (60%)
 Cumulative dose (mCi) 387 (193–599) 294 (146–598) 446 (271–599) 0.295
Other treatments     
 EBRT 24 (29%) 15 (46%) 9 (18%) 0.008
 TKI 11 (13%) 6 (18%) 5 (10%) 0.299
Follow-up (months) 62 (34–103) 56 (31–76) 75 (42–122) 0.088
Death 30 (36%) 16 (49%) 14 (28%) 0.057
Thyroid cancer 26 (31%) 13 (39%) 13 (26%) 0.198
Significant P values displayed in bold.
Abbreviations: EBRT, external beam radiation therapy; HT, hemi-thyroidectomy; IQR, interquartile range; mCi, milliCurie; RAI, radioactive iodine; SD, 
standard deviation; TKI, tyrosine kinase inhibitor; TT, total thyroidectomy.
aValues are means (± SD), medians (25–75 IQR), or numbers (percentages).
bP value comparing metastases pre- and post-RAI groups.
4  van Velsen et al.  2015 ATA Guidelines in Metastatic DTC J Clin Endocrinol Metab, March 2020, 105(3):1–9
Copyedited by: oup
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/105/3/dgz137/5607901 by Erasm
us U
niversiteit R
otterdam
 user on 19 February 2020
resulted in 5 patients with low-risk disease who would 
not have been treated with RAI therapy according to 
the 2015 ATA Guidelines. This resulted in 247 patients 
(ie, 5  +  54  +  188), in whom 5 (2.0%) distant meta-
static disease would have been missed if no RAI therapy 
would have been given. The number of intermediate-
risk patients remained the same. Therefore, there was no 
influence on the percentage of potentially missed distant 
metastases in the group in which RAI therapy should be 
considered.
Response to therapy and survival of patients with 
distant metastases
At the first DRS after initial therapy (median 
10  months), the majority of the patients with distant 
metastases continued to have structural disease (87%), 
while an excellent response was seen in only 5 patients 
(6%). The other patients had either biochemical incom-
plete (1%) or an indeterminate (6%) response. These 
percentages were similar for the pre- and post-RAI 
groups separately (see Table 4). None of the patients 
with an initial excellent response died from thyroid 
cancer during follow-up, while the 10-year DSS of 
patients with an initial structural incomplete response 
was as low as 54%.
During follow-up, only 14 (17%) patients achieved 
NED after a median of 45 months. During the rest of 
follow-up (median 43 months), none of these patients 
experienced a recurrence. NED occurred significantly 
more often in the post-RAI group (P = 0.044), but using 
a Cox proportional hazards model accounting for time, 
this significant difference between both groups disap-
peared (P = 0.106). None of the patients that achieved 
NED died during remaining follow-up.
As none of the patients experienced a recurrence, at 
the end of follow-up, 14 patients (17%) had an excellent 
response. Next to this, 55 patients (67%) still had struc-
tural disease (see Table 5). The other patients had either 
biochemical incomplete (1%) or indeterminate (15%) 
response. In the majority of patients, structural disease 
was still present as distant metastases (96%), but 40% 
also had local disease in the neck region in addition to 
the distant metastases. The patients in whom the dis-
tant metastases were identified on the posttherapy scan, 
Table 3. Characteristics of the ATA Low-Risk Patients in Whom Distant Metastatic Would Have Been Initially 
Missed
Gender, 
Age
Year of 
Diagnosis
Disease  
Type TNM (8th)
Location  
of Distant  
Metastases
s-Tg (ng/ml) 
during first RAI 
therapy
RAI  
Therapy Initial DRS
Time Until 
Excellent 
Response 
Female, 
48 years
2014 PTC; Follicular 
variant
pT1bN0M1 Sternal lesion on 
SPECT/CT
<0.9 (Tg-abs:  
(15.8 U/mL)
Once; 143 
mCi
Excellent 17 months
Female, 
46 years
2006 PTC pT2N0M1 Uptake in Lungs on 
SPECT/CT
22.3 (Tg- abs: 
22.3 U/mL)
Twice; 230 
mCi
Structural 
Incomplete
121 months
Female, 
32 years
2014 FTC; minimally 
invasive
pT2N0M1 Uptake in Lungs on 
SPECT/CT
2.9 Twice; 193 
mCi
Excellent 10 months
Female, 
52 years
2013 PTC pT2N0M1 Uptake in Lungs on 
SPECT/CT
8.6 Twice; 192 
mCi
Indeterminate 38 months
Abbreviations: ATA, American Thyroid Association; DRS, Dynamic Risk Stratification; FTC, follicular thyroid cancer; mCi, milliCurie; PTC, papillary thy-
roid cancer; RAI, radioactive iodine; s-Tg, stimulated thyroglobulin; Tg-abs, thyroglobulin antibodies.
Table 4. Response to Therapy After First Therapy
Total  
Population  
(n = 83)a, b
Pre-RAI 
Group  
(n = 33)a
Post-RAI 
Group  
(n = 50)a
P 
Valueb
Excellent 5 (6%) - 5 (10%) 0.998
Indeterminate 5 (6%) 2 (6%) 3 (6%) 0.991
Biochemical 
Incomplete
1 (1%) - 1 (2%) 0.998
Structural 
Incomplete
72 (87%) 31 (94%) 41 (82%) 0.134
Persistent  
Disease
73 (88%) 31 (94%) 42 (84%) 0.190
aValues are numbers (percentages).
bP-value comparing pre- and post-RAI groups.
Table 5. Response to Therapy at End of Follow-up
Total  
Population  
(n = 82)a
Pre-RAI 
Group  
(n = 33)a
Post-RAI 
Group  
(n = 49)a
P  
Valueb
Excellent 14 (17%) 2 (6%) 12 (25%) 0.044
Indeterminate 12 (15%) 2 (6%) 10 (20%) 0.089
Biochemical 
Incomplete
1 (1%) 1 (3%) - 0.998
Structural 
Incomplete
55 (67%) 28 (85%) 27 (55%) 0.007
Local 24 (43%) 11 (39%) 13 (48%)  
Distant 53 (96%) 28 (100%) 25 (93%)  
Both 22 (40%) 11 (39%) 11 (41%)  
Persistent  
Disease
56 (68%) 29 (88%) 27 (55%) 0.003
Significant P values displayed in bold.
aValues are numbers (percentages).
bP-value comparing pre- and post-RAI groups.
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exhibited an excellent response more often (25% vs 
6%; P  =  0.044), and less frequently had evidence of 
structural disease (55% vs 85%; P = 0.007).
With respect to survival, 10-year OS was 48.5% for 
the whole group, while 5-year and 10-year DSS were 
79.8% and 57.0%, respectively (see Fig. 1). The pre-RAI 
group had a significantly lower 10-year DSS (39.3% vs 
68.3% respectively; P = 0.042). However, when adjusting 
for age and sex, the difference between both groups lost 
statistical significance (P = 0.187; see also Table 6).
Of the 4 patients with distant metastases who would 
not have been treated with RAI therapy, and of the 6 
for whom RAI therapy would have been considered, 
according to the 2015 ATA Guidelines (see also Table 
3), at the first DRS after initial therapy, 3 had an excel-
lent response, while the others had either indeterminate 
(n = 1) or structural incomplete response (n = 6). Six 
patients achieved NED, and the median time to NED 
was 28 months. During the rest of follow-up (median 
29 months), none of these patients experienced a recur-
rence nor died. The other 4 patients had either indeter-
minate (n = 1) or structural incomplete response (n = 3) 
at end of follow-up.
Risk factors
An elevated postoperative stimulated-Tg just before 
RAI therapy, presence of initial lymph node metastases, 
older age, and larger tumor size increased the risk of 
not having an excellent response at end of follow-up 
in a univariate analysis, while an elevated postoperative 
stimulated-Tg, older age, larger tumor size, and having 
FTC increased the risk of having persistent disease at end 
of follow-up (26). Presence of RAI refractory disease, 
older age, and larger tumor size resulted in an increased 
all-cause and thyroid cancer specific mortality (26). An 
elevated postoperative stimulated-Tg, initial presence 
of lymph node metastases, and older age resulted in a 
lower chance of developing NED during follow-up (26).
After adjusting for age and sex, we determined 
that an elevated postoperative stimulated-Tg, initial 
presence of lymph node metastases, and older age 
increased the risk of not having an excellent response 
at final follow-up, while these same factors (except for 
an elevated postoperative stimulated-Tg) increased 
the risk of having persistent disease (26). The pres-
ence of RAI refractory disease and older age still in-
creased all-cause and thyroid cancer specific mortality 
(26). An elevated postoperative stimulated-Tg, initial 
presence of lymph node metastases and older age still 
resulted in a lower chance of developing NED during 
follow-up (26).
Discussion
This study determined that 1.6% of the patients who 
did not have a routine indication for RAI therapy ac-
cording the 2015 ATA Guidelines were found to have 
distant metastases that would have been missed initially 
if no RAI therapy was given. This percentage was 2.5% 
in the patient group in whom RAI therapy should have 
been considered. Furthermore, in patients with initial 
distant metastases, two-thirds still had structural disease 
at end of follow-up, while almost 20% achieved an ex-
cellent response. None of the patients with an excellent 
response experienced a recurrence during the period of 
follow-up.
Figure 1. Kaplan-Meier curves for overall survival (OS) (A) and disease-specific survival (DSS) (B).
Table 6. Effect of Metastases Detection Time on 
Survival
Hazard Ratio (95% CI) P Valuec
OS   
 Model Ia 0.38 (0.18–0.79) 0.009
 Model IIb 0.47 (0.22–1.00) 0.050
DSS   
 Model I a 0.45 (0.21–0.99) 0.047
 Model IIb 0.58 (0.26–1.30) 0.187
Significant P values displayed in bold.
Abbreviations: CI, confidence interval; DSS, disease specific survival; 
OS, overall survival.
aModel I; unadjusted.
bModel II; adjusted for age and sex.
cP value comparing pre- and post-RAI groups (pre-RAI group as refer-
ence group). 
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The recommendation in the 2015 ATA Guidelines 
not to give RAI therapy in ATA low-risk patients is 
based on systematic reviews which did not find a sig-
nificant benefit of RAI therapy on cancer-related death 
(3, 27, 28). Others have argued that the occurrence of 
undetected metastatic disease in these patients is low, 
and rising Tg levels during follow-up would warrant 
the need for further investigations (27). In addition, it 
has been reported that RAI therapy in patients with 
hyperthyroidism might lead to an increased mortality 
risk from secondary solid tumors, but not hematologic 
cancers (29); however, a recent meta-analysis in thyroid 
cancer patients did not provide a clear answer on the 
possible increased risk of secondary malignancies due 
to RAI therapy (30). In the current retrospective study 
we observed that 1.6% of the 246 patients without an 
indication for RAI therapy according to the 2015 ATA 
Guidelines had distant metastases. Those metastases 
would initially have been missed if no RAI therapy was 
given. Although one might argue that due to the char-
acteristics of these patients (Tg-levels, presence of anti-
bodies), closer follow-up was warranted which would 
have led to detection of the metastases, it is unclear 
whether this would have affected prognosis. Due to the 
small number of identified low-risk patients with distant 
metastatic disease, we were unable to search for factors 
that could have identified those patients with distant 
metastatic disease before initial therapy. Albano et  al 
found a slightly higher number as 3.6% of their low-risk 
patients had distant metastases that would have been 
missed using the 2015 ATA Guidelines (13). However, 
they also included patients in whom metastatic disease 
was diagnosed during follow-up. This group is probably 
a different subset of patients, who would probably have 
been investigated for possible presence of distant metas-
tases during follow-up. In contrast, Agate et al found a 
lower number of approximately 1% in low-risk patients 
with distant metastases that would have been missed 
(14). However, these results might not be totally com-
parable as they used the 2009 ATA Guidelines low-risk 
definition. Further, Avram et al. investigated the impact 
of the first whole-body scan on staging, and demon-
strated distant metastases in 5 out of 116 (4.3%) pa-
tients with pT1 tumors (size ≤ 2.0 cm) (31). However, 
because no information about the ATA risk category is 
available from this study, the possible indications for 
RAI therapy could not be determined from their study. 
Furthermore, no separate numbers regarding pT2 tu-
mors (size > 2.0 cm to ≤ 4.0 cm) were given.
The 2015 ATA Guidelines recommend to consider 
RAI therapy in ATA intermediate-risk patients; these 
recommendations are based on literature investigating 
the effect of RAI therapy in patients having one or more 
of the different intermediate-risk criteria; since data are 
conflicting, the recommendation is given to consider 
RAI therapy in these patients (3). As our Dutch guide-
line recommends to always treat patients with RAI 
therapy after a total thyroidectomy, our study popula-
tion is suited to evaluate the proportion of possible un-
detected distant metastases when omitting RAI therapy 
in ATA intermediate-risk patients. We showed that 
2.5% of the patients had distant metastases that would 
have been missed if no RAI therapy was given. Albano 
et al reported that 4.9% would have been missed (13), 
while this proportion was 1.4% in the study of Agate 
et al (14). Differences between these 2 studies and ours 
were mentioned in the previous paragraph.
Evaluating the 2015 ATA Risk Stratification System 
in patients with distant metastases, two-thirds of our 
patients still had structural disease at final follow-up, 
whereas 17% had NED. This suggests that the initial 
risk stratification of patients with distant metastases as 
ATA high-risk is valid. Hirsch et  al found an excellent 
response in 25% of their patients at the end of follow-up, 
but to define an excellent response they used a stimulated 
Tg < 2 ng/mL, rather than < 1 ng/mL as used in our study 
and in the 2015 ATA Guidelines (15). Earlier research 
in ATA high-risk patients, thus including patients with 
distant metastatic disease, showed lower percentages 
of patients with persistent structural disease and higher 
numbers of patients with NED at final follow-up (32, 
33). This difference is probably due to the fact that we 
only studied patients treated at a tertiary referral center 
with distant metastases. However, metastatic disease did 
not influence response to therapy in an earlier study (25). 
Another factor might be age, as we showed that older 
age increases the risk of having persistent disease and not 
having an excellent response; our population is older than 
the populations of 2 earlier studies (32, 33). Data on other 
factors, such as elevated postoperative stimulated-Tg was 
unfortunately unavailable for these 2 studies.
In patients that achieved an excellent response, no 
recurrences occurred (median time from NED to end 
of follow-up was 43  months). Similar results were 
found by Hirsh et  al (15). Chopra et  al found a re-
currence rate of 21% in patients with lung metastases 
(34). However, their definition of an excellent re-
sponse was different (stimulated Tg < 10 ng/mL), and 
therefore their group also included patients having an 
indeterminate response according to the 2015 ATA 
Guidelines. Further, earlier studies in ATA high-risk 
patients found recurrences rates of 14% to 30% (9, 
25, 32, 33, 35). One might argue that a successful 
therapy for distant metastatic disease is also able to 
destroy other thyroid cancer tissue (eg, due to gross 
ETE), resulting in a lower recurrence in these patients. 
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Therefore, the DRS of the ATA Risk Stratification 
System performs well regarding the prediction of re-
current disease after NED.
The 5- and 10-year DSS rates were respectively 80% 
and 57% in our population. This is similar to earlier 
studies (20, 22, 33). On the other hand, Lee et al (16) and 
Goffredo et al (36) found 10-year DSS rates of respect-
ively 27% and 44%, while Nixon et al showed a 5-year 
DSS of 68% (18). Differences might be due to the fact 
that we studied only patients with distant metastases de-
tected before or during initial therapy, while others also 
included patients who developed distant metastases later 
during follow-up (16), or patients that did not receive thy-
roid surgery (36). RAI-refractory disease and older age 
resulted in an increased all-cause and thyroid cancer spe-
cific mortality. These factors were also reported in earlier 
studies identifying risk factors for decreased survival in 
patients with distant metastases (15–17, 20, 21, 36).
One of the main strengths of this study is the sub-
stantial number of patients having distant metastases 
of well-differentiated thyroid carcinoma discovered be-
fore or during initial therapy with a well-documented 
follow-up. This enabled us to evaluate the indications 
for RAI therapy of the 2015 ATA Guidelines, but also 
to investigate disease outcome and prognostic factors. 
Furthermore, unlike this study, many other studies 
evaluated well-differentiated and poorly-differentiated 
thyroid cancer as one group despite their different be-
havior (15, 16, 33). A possible limitation of the current 
study is that patients were recruited from a single ter-
tiary university hospital, which might attract patients 
with more aggressive disease because of the availability 
of advanced treatments. Finally, because of the retro-
spective character of the study, our dataset was incom-
plete in 4% of the (potential) risk factors values. As only 
2 patients had insufficient follow-up information, it is 
unlikely that such a small proportion would have al-
tered the overall results.
In conclusion, this study shows that in DTC pa-
tients without an indication for RAI therapy or in 
whom RAI therapy should be considered respectively 
1.6% and 2.5% have distant metastases that initially 
would be missed if no RAI therapy is given. Further 
research should therefore focus on factors predicting 
in which patients RAI therapy could be omitted safely 
without the risk of missing distant metastatic disease. 
Secondly, the 2015 ATA Guidelines are an excellent 
predictor of both persistent disease and recurrence in 
patients with initial metastatic disease, since at the 
end of follow-up, two-thirds of the patients still had 
structural disease, and none of the patients with an 
excellent response during follow-up experienced a re-
currence later-on.
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